Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Proglucamune
- Development stage
- Unknown
- Lead developer
- USANA Health Sciences
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Proglucamune is a dietary supplement formulated to support and prime the immune system. It combines antioxidant-rich, organic reishi and shiitake mushroom extracts with a unique strain of baker’s yeast (providing beta-glucan) and zinc. The primary mechanism involves beta-glucans binding to receptors on immune cells—such as macrophages, neutrophils, and natural killer cells—priming them for a rapid response without overstimulating the immune system. Zinc supports healthy signaling between immune cells. Proglucamune is designed for daily use in healthy adults, athletes, or individuals under occasional stress to help maintain overall wellness and robust immunity[1][2][4][5][7][9]. Clinical studies have evaluated its effect on "Protective Qi" (PQi), an innate immunity concept in Traditional Chinese Medicine (TCM), showing statistically significant improvement in PQi status among users[3][6][8].
- Brand names
- Proglucamune
02
Targets
TLR2 (Toll-like Receptor 2)CLEC7A (Dectin-1)αMβ2 (Integrin αMβ2)
Beyond the preview
Go deeper on Proglucamune.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proglucamune.